Elevar Is Committed
to Supporting Patients Throughout Their Treatment Journey With Elevar Care Connect

NOW APPROVED!

Available Soon

LYRFIGTU™ is indicated for the
treatment of adults
with previously
treated, unresectable, locally
advanced or metastatic
cholangiocarcinoma
harboring a
fibroblast growth factor receptor 2
(FGFR2) fusion or
other rearrangement.

Prescribing Information for LYRFIGTU (lirafugratinib)